Companies are adopting diverse approaches to reducing unwanted toxicities associated with cell and gene therapy.

A new platform identifies which genes drive particle assembly to engineer cells that yield more potent delivery vehicles.

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

Gene editing has emerged as a powerful approach for targeting the genetic causes of disease, but getting the editing ...

The Scottish Medicines Consortium (SMC) has accepted exagamglogene autotemcel (Casgevy, Vertex Pharmaceuticals) for use within NHS Scotland to treat sickle cell disease (SCD) in patients aged 12 years ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...

Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important signaling molecules can become diluted as these cells grow and divide, causing ...

Researchers at EPFL have developed CenSpark, a fluorescent probe that selectively labels centrioles and cilia in living cells across species. The tool enables high-precision, real-time imaging of ...

A robust and quantitative map links chromatin modification and gene expression of cells during zebrafish embryogenesis.